The Capital Desert
Cannabis venture capital investment cratered from $3 billion in 2019 to ~$410 million in 2024. Total cannabis capital raised was ~$2.2 billion in 2024 (+18% YoY), but 91–94% was debt — equity markets have, in the words of Viridian Capital Advisors’ Frank Colombo, “completely gone away” for U.S. cultivators. The average deal size grew to $17.5M even as deal count fell 19% (from 156 to 126), indicating concentration in fewer, larger operators.
The average cost of cannabis debt runs 10–18.5%, far above traditional corporate rates. The MSOS ETF has declined roughly 90% from its February 2021 high.
Why Capital Left
- Federal illegality — institutional investors (pension funds, mutual funds, major VCs) cannot or will not hold cannabis equity while it remains Schedule I
- 280E tax burden — operators cannot deduct normal business expenses, crushing cash flow and making growth nearly impossible to self-fund
- Rescheduling fatigue — investors who entered in 2019–2021 betting on federal reform have been waiting 3–5+ years without resolution
- Operator economics — with only 27.3% of operators profitable, the investment thesis of “legalization creates automatic growth” has proven false
- No exit path — cannabis companies cannot list on major U.S. exchanges, limiting M&A and IPO exit opportunities
Where Capital Is Flowing
What little investment remains is concentrated in specific areas:
- Limited-license MSOs — companies with licenses in high-barrier states (IL, NJ, FL, CT) attract the most interest due to defensible margins
- Cannabis technology — compliance software, POS systems, seed-to-sale tracking, and data analytics platforms can serve the industry without touching the plant
- Real estate / sale-leasebacks — cannabis REITs (Innovative Industrial Properties, etc.) provided capital in exchange for long-term lease obligations, though this model has strained as operators struggle with rent
- International markets — German legalization (2024) and other international developments have attracted some capital that previously targeted U.S. opportunities
- Debt over equity — investors increasingly prefer secured debt with high interest rates over equity positions, reflecting risk aversion
Top U.S. MSOs by Revenue (FY 2025)
| Company | FY 2025 Rev | YoY | EBITDA Margin | Stores |
|---|---|---|---|---|
| Curaleaf | ~$1,270M | −5% | 22% | 159 |
| Trulieve | $1,181M | −0.4% | 36% | 233 |
| Green Thumb | ~$1,175M | +3.4% | 30% | 113 |
| Verano | $822M | −6.5% | 28% | ~130 |
| Cresco Labs | $656M | −8% | 24% | 73 |
| Ascend Wellness | $501M | N/A | 23% | 48 |
Source: Q4/FY 2025 earnings releases (Feb–Mar 2026). Only Green Thumb posted meaningful organic revenue growth. Trulieve leads on margins (60% gross, record $427M adj. EBITDA). Curaleaf is the only MSO with significant international revenue ($51M/quarter, 15% of sales, 15 countries).
The Rescheduling Catalyst
If the DEA reclassifies cannabis from Schedule I to Schedule III, the investment landscape would change dramatically:
- 280E elimination — operators could deduct ordinary business expenses, potentially doubling or tripling net income overnight
- Institutional access — major exchanges may begin listing cannabis companies, opening the door to institutional capital
- Banking reform — rescheduling would de-risk banking relationships even without SAFE Banking passage
- M&A acceleration — consumer brands (alcohol, pharma, CPG) that have been waiting on the sidelines could enter through acquisitions
However, rescheduling has been “imminent” for years. Investors who positioned for it in 2021–2023 have suffered significant losses waiting.
Investment intelligence. The Green Forecast quarterly report tracks capital flows, M&A activity, and public market performance alongside named cultural trend forecasting. Our State Reports include local investment landscape assessments.